64
Views
0
CrossRef citations to date
0
Altmetric
Letters to the Editor

Prevalence and factors of polypharmacy among disease-free survivors of adults after allogeneic hematopoietic cell transplantation

, , , , , , , , , & ORCID Icon show all
Pages 516-520 | Received 08 Nov 2023, Accepted 19 Dec 2023, Published online: 27 Dec 2023
 

Acknowledgments

The authors thank all of the physicians and staff at our hospital.

Author contributions

E.M. collected data, analyzed data, and contributed to writing the paper. T.K. conceived the project, designed the research, collected data, analyzed data, and wrote the paper. All the other authors participated in the treatment of the patients, acquired the clinical data, and contributed to writing the paper. All authors approved the final version.

Ethical approval

The Institutional Review Board of the Institute of Medical Science, University of Tokyo approved this cross-sectional study (2023-29-0708), and the use of an opt-out consent mechanism in this cross-sectional study.

Disclosure statement

No potential conflict of interest was reported by the author(s).

Data availability statement

The data that support the findings of this study are available from the corresponding author upon reasonable request.

Additional information

Funding

The author(s) reported there is no funding associated with the work featured in this article.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.